These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7534387)

  • 1. Dopaminergic and muscarinic regulation of striatal enkephalin and substance P messenger RNAs following striatal dopamine denervation: effects of systemic and central administration of quinpirole and scopolamine.
    Nisenbaum LK; Kitai ST; Gerfen CR
    Neuroscience; 1994 Nov; 63(2):435-49. PubMed ID: 7534387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion.
    Nisenbaum LK; Kitai ST; Crowley WR; Gerfen CR
    Neuroscience; 1994 Jun; 60(4):927-37. PubMed ID: 7523989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial striatal dopamine depletion differentially affects striatal substance P and enkephalin messenger RNA expression.
    Nisenbaum LK; Crowley WR; Kitai ST
    Brain Res Mol Brain Res; 1996 Apr; 37(1-2):209-16. PubMed ID: 8738153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrastriatal injection of a muscarinic receptor agonist and antagonist regulates striatal neuropeptide mRNA expression in normal and amphetamine-treated rats.
    Wang JQ; McGinty JF
    Brain Res; 1997 Feb; 748(1-2):62-70. PubMed ID: 9067445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
    Chen JF; Aloyo VJ; Weiss B
    Neuroscience; 1993 Jun; 54(3):669-80. PubMed ID: 8101360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum.
    Jolkkonen J; Granata R; Jenner P; Marsden CD
    Neuropeptides; 1995 Aug; 29(2):109-14. PubMed ID: 7477761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine-treated rats.
    Wang JQ; McGinty JF
    Neuroscience; 1996 Nov; 75(1):43-56. PubMed ID: 8923522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE; Wooten GF
    Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis.
    Gerfen CR; McGinty JF; Young WS
    J Neurosci; 1991 Apr; 11(4):1016-31. PubMed ID: 1707092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels.
    Cenci MA; Campbell K; Björklund A
    Neuroscience; 1993 Nov; 57(2):275-96. PubMed ID: 8115038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
    Sivam SP; Breese GR; Krause JE; Napier TC; Mueller RA; Hong JS
    J Neurochem; 1987 Nov; 49(5):1623-33. PubMed ID: 2889804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
    Engber TM; Boldry RC; Kuo S; Chase TN
    Brain Res; 1992 May; 581(2):261-8. PubMed ID: 1356580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Turgeon SM; Fink JS
    Neuroscience; 1997 Jul; 79(1):79-93. PubMed ID: 9178866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia.
    Salin P; Hajji MD; Kerkerian-le Goff L
    Eur J Neurosci; 1996 Aug; 8(8):1746-57. PubMed ID: 8921265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D2 dopaminergic regulation of striatal preproenkephalin mRNA levels is mediated at least in part through cholinergic interneurons.
    Pollack AE; Wooten GF
    Brain Res Mol Brain Res; 1992 Mar; 13(1-2):35-41. PubMed ID: 1315917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postnatal administration of D1 dopamine agonist reverses neonatal dopaminergic lesion-induced changes in striatal enkephalin and substance P systems.
    Sivam SP; Cox J
    Brain Res; 2006 Feb; 1073-1074():159-63. PubMed ID: 16455064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic blockade of muscarinic cholinergic receptors by systemic trihexyphenidyl (Artane) administration modulates but does not mediate the dopaminergic regulation of striatal prepropeptide messenger RNA expression.
    Mavridis M; Rogard M; Besson MJ
    Neuroscience; 1995 May; 66(1):37-53. PubMed ID: 7637873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.